Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK

NCT06666348 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Pediatric Low-grade Glioma

Interventions

DRUG: Mirdametinib

Sponsor

St. Justine's Hospital